Marshall Wace LLP Raises Holdings in Insmed Incorporated (NASDAQ:INSM)

Marshall Wace LLP increased its position in Insmed Incorporated (NASDAQ:INSM) by 38.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,064,215 shares of the biopharmaceutical company’s stock after buying an additional 293,004 shares during the period. Marshall Wace LLP’s holdings in Insmed were worth $73,473,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. National Bank of Canada FI increased its stake in Insmed by 9.7% in the 4th quarter. National Bank of Canada FI now owns 1,668 shares of the biopharmaceutical company’s stock worth $115,000 after acquiring an additional 147 shares during the last quarter. Abel Hall LLC increased its position in Insmed by 4.7% in the fourth quarter. Abel Hall LLC now owns 3,333 shares of the biopharmaceutical company’s stock worth $230,000 after purchasing an additional 151 shares during the last quarter. Steward Partners Investment Advisory LLC raised its stake in Insmed by 65.2% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 163 shares in the last quarter. M&T Bank Corp lifted its position in Insmed by 5.6% during the fourth quarter. M&T Bank Corp now owns 3,146 shares of the biopharmaceutical company’s stock valued at $217,000 after purchasing an additional 166 shares during the last quarter. Finally, Nisa Investment Advisors LLC lifted its position in Insmed by 5.5% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,533 shares of the biopharmaceutical company’s stock valued at $244,000 after purchasing an additional 183 shares during the last quarter.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on INSM shares. Royal Bank of Canada restated an “outperform” rating and set a $100.00 target price on shares of Insmed in a research report on Wednesday, March 19th. Bank of America upped their price objective on Insmed from $92.00 to $96.00 and gave the company a “buy” rating in a research report on Thursday, March 20th. Morgan Stanley lifted their target price on Insmed from $85.00 to $90.00 and gave the stock an “overweight” rating in a report on Thursday, February 6th. Wells Fargo & Company increased their price target on Insmed from $85.00 to $107.00 and gave the company an “overweight” rating in a report on Wednesday, February 19th. Finally, Truist Financial lifted their price objective on shares of Insmed from $105.00 to $108.00 and gave the stock a “buy” rating in a research note on Friday, February 21st. One equities research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $94.00.

Insmed Price Performance

Insmed stock opened at $70.20 on Thursday. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. The stock has a market cap of $12.76 billion, a price-to-earnings ratio of -12.56 and a beta of 1.07. The firm has a 50-day moving average of $75.60 and a two-hundred day moving average of $73.60. Insmed Incorporated has a 1 year low of $21.92 and a 1 year high of $84.91.

Insmed (NASDAQ:INSM) last announced its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.15). The firm had revenue of $104.44 million during the quarter, compared to analysts’ expectations of $102.31 million. Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. On average, research analysts forecast that Insmed Incorporated will post -4.56 earnings per share for the current year.

Insiders Place Their Bets

In related news, CEO William Lewis sold 6,830 shares of the business’s stock in a transaction that occurred on Tuesday, April 15th. The shares were sold at an average price of $70.16, for a total value of $479,192.80. Following the completion of the transaction, the chief executive officer now owns 233,924 shares of the company’s stock, valued at $16,412,107.84. The trade was a 2.84 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Orlov S. Nicole Schaeffer sold 91,140 shares of the company’s stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $80.00, for a total value of $7,291,200.00. Following the sale, the insider now owns 97,083 shares of the company’s stock, valued at approximately $7,766,640. This represents a 48.42 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 471,797 shares of company stock worth $37,621,239. 3.00% of the stock is currently owned by company insiders.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.